Department of Surgery »  Faculty »  Sang-Mo Kang, M.D.

Sang-Mo Kang, M.D.

Associate Professor of Surgery
Division of Transplant Surgery
Surgical Director, Intestinal Rehabilitation and Transplantation

Contact Information

Academic Office
(415) 476-0789 
sang-mo.kang@ucsfmedctr.org

Connie Frank Transplant Center at UCSF
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1551
Phone: (888) 894-6361

Intestinal Rehabilitation & Transplantation Program
350 Parnassus Ave., Suite 410
San Francisco, CA 94143
Phone: (415) 353-2336
Liver Transplant Program
400 Parnassus Ave., Sixth Floor
San Francisco, CA 94143
Phone: (415) 353-1888

Pancreas Transplant Services
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1551
Phone: (888) 894-6361

Education

  • Cornell University, B.A., Chemistry, with Distinction, 1982-86
  • Harvard Medical School, Boston, MA, M.D., Magna Cum Laude 1986-92

Residencies

  • University of California, San Francisco, Intern and Resident, General Surgery Program, 1992-95
  • University of California, San Francisco, Resident, General Surgery Program, 1997-99

Fellowships

  • University of California, San Francisco, Fellow, Transplant Surgery, 1999-01

Postdoctoral Training

  • University of California, San Francisco, Postdoctoral Fellow , Immunology and Transplantation, 1995-97

Board Certifications

  • American Board of Surgery, 2000

Program Affiliations

  • UCSF Intestinal Rehabilitation and Transplantation
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • The Liver Center at UCSF
  • Diabetes Center at UCSF

Clinical Expertise

Research Interests

  • Dendritic Cell Immune Therapy
  • Novel Strategies for the Induction of Transplant-specific Tolerance
  • T-cell Mediated Transplant Rejection as well as Tolerance
  • Transplant Immunology

Biography

Dr.Sang-Mo Kang is an Associate Professor of Surgery and transplant surgeon. He joined the UCSF School of Medicine faculty in 2001 and in 2005 was named Surgical Director of Intestinal Rehabilitation and Transplantation at UCSF Medical Center.  Dr. Kang takes care of both adult and pediatric patients and performs kidney, liver, pancreas and intestinal transplants as well as surgery for numerous hepatobiliary and gastrointestinal diseases.  

Dr. Kang received his B.S. in chemistry from Cornell University and his M.D. from Harvard University Medical School.  He completed a general surgery residency, and immunology and clinical transplantation fellowships at University of California, San Francisco.  Dr Kang was recognized with two Howard Hughes Medical Institute Fellowships, one during medical school and one during his residency. 

Dr. Kang's current research  focus is in the development of novel strategies for the induction of transplant-specific tolerance. Dr. Kang has published numerous articles in medical and scientific journals and been invited to present at national and international seminars and conferences.  

Dr. Kang is a member of numerous medical societies including American Society of Transplant Surgeons, American College of Surgeons, American Association of Immunologists, National Kidney Foundation, Association for Academic Surgery, and Society of University Surgeons.

 

Research Overview

The Kang Lab is developing novel strategies for the induction of transplant-specific tolerance. The research focuses on achieving what is known as "allo-specific transplant tolerance",  a specialized method of preventing the rejection of a transplanted organ without suppressing the entire immune system. 

Currently, transplant recipients must receive immunosuppressive drugs to suppress their own white blood cells (T cells) that attack foreign cells and cause organ rejections.  Unfortunately, these non-specific drugs affect the entire immune system and thus carry significant risks for infection and certain malignancies. The goal is to eliminate the need for global immunosuppression in transplant recipients.  Ideal immunotherapy would be one that targets only the donor-specific immune cells that cause rejection, without affecting any of the other immune cells, thus leaving the immune system intact and able to function at full capacity.

To this end, the lab is conducting several experiments to gain insight into the mechanisms of rejection.  These projects include the use of specialized immune cells in targeting specific lymphoid organs, as well as investigations into the contributions of CD+4 T cells and CD8 T cells to the process of transplant rejection.  The laboratory's work is helping to define important parameters for potential treatments in humans.

 

Publications

Most recent publications from a total of 37
  1. Lee RH, Roll G, Nguyen V, Willenbring H, Tang Q, Kang SM, Stock PG. Failure to Achieve Normal Metabolic Response in Non-Obese Diabetic Mice and Streptozotocin-Induced Diabetic Mice After Transplantation of Primary Murine Hepatocytes Electroporated With the Human Proinsulin Gene (p3MTChins). Transplant Proc. 2014 Jul-Aug; 46(6):2002-6. View in PubMed
  2. Lee RH, Roll G, Nguyen V, Willenbring H, Tang Q, Kang SM, Stock PG. Failure to Achieve Normal Metabolic Response in Non-Obese Diabetic Mice and Streptozotocin-Induced Diabetic Mice After Transplantation of Primary Murine Hepatocytes Electroporated With the Human Proinsulin Gene (p3MTChins). Transplant Proc. 2014 Jul-Aug; 46(6):2002-6. View in PubMed
  3. Lee K, Nguyen V, Lee KM, Kang SM, Tang Q. Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy. Am J Transplant. 2014 Jan; 14(1):27-38. View in PubMed
  4. Gupta N, Henry RG, Strober J, Kang SM, Lim DA, Bucci M, Caverzasi E, Gaetano L, Mandelli ML, Ryan T, Perry R, Farrell J, Jeremy RJ, Ulman M, Huhn SL, Barkovich AJ, Rowitch DH. Neural stem cell engraftment and myelination in the human brain. Sci Transl Med. 2012 Oct 10; 4(155):155ra137. View in PubMed
  5. Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F. Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Transpl Int. 2012 Dec; 25(12):1257-67. View in PubMed
  6. Nijagal A, Fleck S, Hills NK, Feng S, Tang Q, Kang SM, Rosenthal P, MacKenzie TC. Decreased risk of graft failure with maternal liver transplantation in patients with biliary atresia. Am J Transplant. 2012 Feb; 12(2):409-19. View in PubMed
  7. Tang Q, Bluestone JA, Kang SM. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol. 2012 Feb; 4(1):11-21. View in PubMed
  8. Lopez-Vergès S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, Houchins JP, Miller S, Kang SM, Norris PJ, Nixon DF, Lanier LL. Expansion of a unique CD57?NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A. 2011 Sep 6; 108(36):14725-32. View in PubMed
  9. Ahearn AJ, Posselt AM, Kang SM, Roberts JP, Freise CE. Experience with laparoscopic donor nephrectomy among more than 1000 cases: low complication rates, despite more challenging cases. Arch Surg. 2011 Jul; 146(7):859-64. View in PubMed
  10. Alemi F, Kwon E, Freise C, Kang SM, Hirose R, Stewart L, Corvera CU. Hepatic surgery at a VA tertiary medical center: lessons learned. Am J Surg. 2010 Nov; 200(5):591-5. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Sang-Mo Kang, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X